| Clinical data | |
|---|---|
| Other names | OPT-302 |
| Routes of administration | Intravitreal |
| Drug class | VEGF-C and VEGF-D inhibitor |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
| ChEMBL | |
  (what is this?) | |
Sozinibercept was an investigational drug intended to be used to treat certain eye conditions such as wet age-related macular degeneration (AMD). It is administered intravitreally in combination with other Anti-VEGF-A including aflibercept, faricimab, ranibizumab, and bevacizumab. [1] It is developed by Opthea. It was granted Fast track designation by the United States Food and Drug Administration (FDA). [2]
Sozinibercept is a “trap” fusion protein that targets vascular endothelial growth factors C and D (VEGF-C and VEGF-D), aiming to inhibit abnormal blood vessel growth and fluid leakage in retinal diseases such as wet age-related macular degeneration (AMD). [3] Sozinibercept is synergistic with anti–VEGF-A therapies because it targets and neutralizes VEGF-C and VEGF-D, while anti–VEGF-A drugs inhibit only VEGF-A; this combined blockade suppresses a broader range of VEGF-driven pathways involved in abnormal blood vessel growth and vascular leakage in retinal diseases. [3]
Despite promising results in early-phase clinical trials, recent late-stage trials failed to meet their primary endpoints for vision improvement, leading to the discontinuation of its development for wet AMD. [4]